Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.050
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
June 10, 2021
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co...
Via
Benzinga
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
June 09, 2021
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said.
Via
Investor's Business Daily
Why Shares of MindMed Dropped 13% in May
June 09, 2021
Froth from its uplisting is having an impact.
Via
The Motley Fool
J.R. Rahn Steps Down As MindMed CEO
June 09, 2021
Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as M...
Via
Benzinga
What Do You Really Know About Psychedelics And Psychedelics Stocks?
June 08, 2021
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That...
Via
Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
June 08, 2021
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
June 07, 2021
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ...
Via
Benzinga
The Mind Medicine Stock Story Has an Awful Lot of Holes in It
June 03, 2021
MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time.
Via
InvestorPlace
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
June 02, 2021
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at...
Via
Talk Markets
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
May 27, 2021
Welcome to the Cannabis...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Mind Medicine Stock Is Not a Trip To Take Just Yet
May 27, 2021
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
Via
InvestorPlace
Topics
Cannabis
Law Enforcement
Exposures
Cannabis
Legal
MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System
May 24, 2021
MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of...
Via
Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
May 24, 2021
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:
Via
Benzinga
Cannabis Movers & Shakers: The Parent Company, MindMed, Australis, Flourish Software
May 20, 2021
The Parent Company Welcomes Desiree Perez To Its Board TPCO Holding Corp. (OTCQX:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
The Jury’s Still Out on Psychedelics Play MindMed Stock
May 20, 2021
Selling off after its NASDAQ uplisting, it's hard to tell whether MNMD stock will soar higher following recent positive developments.
Via
InvestorPlace
MindMed To Conduct The First Modern Research On Mescaline In Switzerland
May 20, 2021
MindMed (NASDAQ: MNMD) (NE...
Via
Benzinga
Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen
May 20, 2021
MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline.
Via
Investor's Business Daily
22 Stocks Moving in Wednesday's Pre-Market Session
May 19, 2021
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares rose 29.6% to $0.6289 in pre-market trading after jumping over 14% on Tuesday. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 16.3%...
Via
Benzinga
Strong Cash Balance Should Provide a Foundation for MindMed Stock
May 18, 2021
Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence.
Via
InvestorPlace
MNMD Stock: The Big News That Has MindMed Investors Psyched Today
May 17, 2021
MindMed (MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development.
Via
InvestorPlace
Exposures
Product Safety
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
May 17, 2021
After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy,...
Via
Benzinga
Exposures
Product Safety
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
May 17, 2021
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
May 13, 2021
Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday. MindMed...
Via
Benzinga
Benzinga Global Small Cap Conference: How Do Investors Pick Winners In The Psychedelics Space?
May 13, 2021
Simeon Schnapper, a managing partner at JLS Fund, took 30 minutes from his busy schedule to share his insights into what makes a w...
Via
Benzinga
Video: Psychedelic Stocks With JLS Fund's Simeon Schnapper & MindMed's JR Rahn
May 13, 2021
During the Benzinga Global Small-Cap Conference on Thursday morning, psychedelics executives discussed the markets and companies' prospects.
Via
Benzinga
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
May 11, 2021
Welcome to the Cannabis Countdo...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
May 10, 2021
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound...
Via
Benzinga
Video: The Psychedelics Market With Entheon Biomedical, MagicMed, Natan Ponieman
May 06, 2021
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Patrick&...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
May 05, 2021
Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.
Via
Talk Markets
The Next Psychedelic Stock To Uplist On The Nasdaq?
May 04, 2021
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?
Via
Talk Markets
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.